# Atriumfibrilleren en hartfalen bij vrouwen: meer symptomen, meer HFpEF en minder ablatie

*geplaatst 2026-11-13 · Hartfalen · Current heart failure reports · doi 10.1007/s11897-026-00790-9 · https://hartvaat.nl/2026/11/06/atriumfibrilleren-en-hartfalen-bij-vrouwen-meer-symptomen-meer-hfpef-en-minder-a/*

Deze overzichtsstudie brengt de epidemiologie, pathofysiologie en behandeling in kaart bij vrouwen met een combinatie van atriumfibrilleren en hartfalen. Vrouwen ontwikkelen vaker atriumfibrilleren op hogere leeftijd, presenteren zich vaker met hypertensie en HFpEF, en ervaren een grotere symptoomlast en lagere levenskwaliteit. Ondanks deze verschillen blijven vrouwen ondervertegenwoordigd in trials en krijgen ze minder vaak ablatie of device-therapie. Klinisch inzicht in dit fenotype is essentieel voor betere risicostratificatie en gepersonaliseerde zorg.

## English: Female Fingerprint: Sex-Specific Aspects in Patients With Atrial Fibrillation and Heart Failure.

This narrative review synthesizes current evidence on sex-specific differences in patients with concomitant atrial fibrillation and heart failure. Women typically present at an older age, more frequently with HFpEF and hypertension, and report a higher symptom burden and reduced quality of life compared to men. Despite these distinct clinical and biological phenotypes, women remain underrepresented in trials and are less likely to receive rhythm-control strategies or device therapy. Recognizing these sex-specific patterns is crucial for refining risk stratification and advancing precision cardiovascular care.

## Abstract (original, from the publication)

PURPOSE OF REVIEW: Atrial fibrillation (AF) and heart failure (HF) frequently coexist and represent a major source of cardiovascular morbidity and mortality. This review summarizes current evidence on sex-specific differences in epidemiology, pathophysiology, clinical presentation, prognosis, and treatment in women with AF and HF. RECENT FINDINGS: Emerging evidence indicates that women with AF and HF constitute a distinct clinical and biological phenotype. Women typically develop AF at older age, more commonly present with hypertension and HF with preserved ejection fraction (HFpEF), and report greater symptom burden and impaired quality of life. Sex-specific mechanisms including hormonal influences, atrial fibrosis, endothelial dysfunction, inflammation, autonomic dysregulation, and microvascular disease contribute to these differences. Population studies further demonstrate sex-related disparities in HF development and outcomes across AF subtypes. Despite increasing awareness, women remain underrepresented in clinical trials and are less likely to receive rhythm-control strategies, catheter ablation, or device therapy. Recognition of the "female fingerprint" in AF and HF is essential for individualized risk stratification and the advancement of precision cardiovascular medicine.

Auteurs: Esther Roth, Laura Rottner

---
Bron: Current heart failure reports, https://doi.org/10.1007/s11897-026-00790-9. Bijgewerkt 2026-11-07T02:10:36Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.